Table 2 Clinical genetic and questions addressing lung transplantation
In patients with familial ILD undergoing lung transplant work up do you (n)*: | Yes | No | Don’t know |
|---|---|---|---|
Measure peripheral blood leukocyte telomere length (196)? | 12% | 41% | 47% |
Refer patients for genetic testing (193)? | 29% | 25% | 46% |
At your transplant centre, will identification of: | Yes | No | Don’t know |
A telomere-related gene variant prevent transplantation (176)? | 6% | 73% | 21% |
A telomere length < the 10th percentile prevent transplantation (176)? | 8% | 72% | 20% |
A surfactant protein variant prevent transplantation (177)? | 6% | 77% | 17% |
Treatment protocol following lung transplantation Will identification of: | Yes | No | |
A telomere length < 10th percentile modify treatment protocol (173)? | 33% | 67% | |
A telomere related gene variant modify treatment protocol (173)? | 33% | 67% | |
If a patient is known with a pathogenic variant in telomere related genes. Will you: | Yes | No | Sometimes |
Offer the patient treatment with immunomodulatory drugs (183)? | 11% | 56% | 33% |